Nisan 2025
Proton pompa inhibitörlerini ne kadar dogru kullaniyoruz? Tek merkez deneyimi
The appropriate use of proton pump inhibitors: Singlecentre experience
- Ana Sayfa
- Sayılar
- Nisan 2025
- Proton pompa inhibitörlerini ne kadar dogru kullaniyoruz? Tek merkez deneyimi...
Özet
Giris ve Amaç:Proton pompa inhibitörleri, gastrik asit sekresyonunu etkili bir sekilde bloke eden ilaçlardir. Tüm dünyada kullanim-lari artmaktadir. Bununla birlikte, gereksiz ve endikasyon disi proton pompa inhibitörü kullaniminin da ciddi sekilde arttigi gözlemlenmektedir. Bu çalismanin amaci, proton pompa inhibitörleri kullaniminin uygunlugunu degerlendirmektir.Gereç ve Yöntem:Bu çalisma, tek merkezli vekesitsel bir gözlem çalismasi olarak gerçeklestirilmistir. 10 Mart 2022- 10 Nisan 2022 tarihleri arasinda Mersin Üniversitesi Tip Fakültesi Gastro-enteroloji Klinigine yatirilan hastalar incelendi. Hastalarin yatis nedenleri, demogra?k verileri, yatis öncesi ve sonrasi ilaç kullanimlari klinik ekibi çalismanin farkinda olmadan kaydedildi.Bulgular:Çalisma döneminde 106 hasta klinige yatirildi. Hastalarin %53’ü erkek olup, yas ortalamasi65.8 yil idi. Yatis nedenleri arasinda en sik görülenler gastrointestinal sistem kanamasi, akut pankreatit ve karin agrisi etiyolojisi arastirilmasi olarakbelirlendi. Yatan hastalarin 45’i (%42) evde proton pompa inhibitörleri kullanirken bunlarin 24’ünde (%53) uygun endikasyon vardi. Hastanede yatis sirasinda proton pompa inhibitörleri kullanan 92 (%86.7) hastanin ise 41’inde (%44.6) proton pompa inhibitörleri kullanimi endikasyonauygundu.Sonuç:Proton pompa inhibitörleri asit ile iliskili hastaliklarin tedavisinde temel ilaçlar arasinda yer almakta ve düsük yan etki pro?llerisayesinde yaygin olarak kullanilmaktadir. Ancak, bu durum gereksiz kullanim riskini de beraberinde getirmektedir. Az da olsa ciddi yan etkiler, mali yük ve polifarmasi gibi dezavantajlarin önemi çalismalar ile vurgulanmalidir.
Abstract
Background and Aims:Proton pump inhibitors are a class of pharmaceuticals that effectively inhibit gastric acid secretion.Their utilisation is increasing on a global scale. However, the use of proton pump inhibitors for off-label and unnecessary indications has also increased signi?cantly. The aim of this study was to evaluate the appropriateness of proton pump inhibitor use.Materials and Methods:Thisstudy was conducted as a single-centre, cross-sectional observational study. Between 10 March 2022 and 10 April 2022, patients admitted to theGastroenterology Clinic of Mersin University Faculty of Medicine were examined. The reasons for hospitalisation, demographic data, and pre- and post-hospitalisation drug use of the patients were recorded without the clinical team being aware of the study.Results:During the study period,106 patients were hospitalised in the clinic, with 53% of the patients being male and the mean age being 65.8 years. The most common reasonsfor hospitalisation were gastrointestinal bleeding, acute pancreatitis and abdominal pain. While 45 (42%) of the hospitalised patients used proton pump inhibitors at home, 24 (53%) of them had appropriate indication. Of the 92 (86.7%) patients who used proton pump inhibitors during hos-pitalisation, 41 (44.6%) had appropriate indication.Conclusion:Proton pump inhibitors represent a class of pharmaceutical agents commonlyprescribed for the management of acid-related pathologies, characterised by their favourable safety pro?le and broad accessibility. However, this widespread utilisation carries inherent risks, including the potential for inappropriate prescriptions. It is imperative to underscore the signi?canceof potential drawbacks, such as adverse effects of a minor severity, ?nancial implications and the necessity for polypharmacy, as highlighted inextant research.
